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Abstract
The objective of this study is to retrospectively report the results of interventions for controlling a vancomycin-resistant entero-
coccus (VRE) outbreak in a tertiary-care pediatric intensive care unit (PICU) of a University Hospital. After identification of the 
outbreak, interventions were made at the following levels: patient care, microbiological surveillance, and medical and nursing 
staff training. Data were collected from computer-based databases and from the electronic prescription system. Vancomycin use 
progressively increased after March 2008, peaking in August 2009. Five cases of VRE infection were identified, with 3 deaths. 
After the interventions, we noted a significant reduction in vancomycin prescription and use (75% reduction), and the last case 
of VRE infection was identified 4 months later. The survivors remained colonized until hospital discharge. After interventions 
there was a transient increase in PICU length-of-stay and mortality. Since then, the use of vancomycin has remained relatively 
constant and strict, no other cases of VRE infection or colonization have been identified and length-of-stay and mortality re-
turned to baseline. In conclusion, we showed that a bundle intervention aiming at a strict control of vancomycin use and full 
compliance with the Hospital Infection Control Practices Advisory Committee guidelines, along with contact precautions and 
hand-hygiene promotion, can be effective in reducing vancomycin use and the emergence and spread of vancomycin-resistant 
bacteria in a tertiary-care PICU.
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Vancomycin overuse has been a concern for many 
years because of its role in selecting vancomycin-resistant 
enterococci (VRE) and vancomycin-resistant Staphylococ-
cus aureus (VRSA) (1,2). In fact, correlations between 
antimicrobial consumption and resistance have already 
been demonstrated (3). VRE are usually resistant to other 
antimicrobials, are easily transmitted in the hospital setting 
and may transfer vancomycin resistance to other Gram-
positive organisms (4). In fact, VRSA has been already 
reported, carrying the enterococcal vanA gene complex, 
with altered cell wall composition and high resistance to 
both oxacillin and vancomycin (5).
In response to the increasing vancomycin misuse, in 
1995, the United States Centers for Disease Control and 
Prevention - Hospital Infection Control Practices Advisory 
Committee (CDC-HICPAC) released the Recommenda-
tions for Preventing the Spread of Vancomycin Resistance, 
which contain instructions for prudent vancomycin use, 
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role of microbiology laboratories in detection, reporting 
and control of VRE, as well as preventing and controlling 
nosocomial transmission of VRE (6). Since then, several 
groups have evaluated vancomycin use at their own insti-
tutions, and the reported prevalence of inappropriate use 
varied widely (20-100%) in adults and children, primarily 
due to empirical therapy (1,2,4,7-14). Recently, some of the 
HICPAC guidelines have been modified to reflect the need 
to empirically cover novel penicillin-resistant pneumococci 
and methicillin-resistant S. aureus (MRSA) (2).
Despite the HICPAC guidelines, multidrug-resistant 
bacterial infections have increased among Pediatric (PICU) 
and Neonatal (NICU) Intensive Care Units with impact 
on major outcomes such as mortality, length-of-stay and 
costs (15,16).
In our institution, since 1998, the protocol for prophy-
laxis of bacterial infection in children undergoing open 
heart surgery has included vancomycin for those admit-
ted 2 days or more before surgery, and vancomycin has 
been initiated against any suspected nosocomial infection 
in the postoperative period. Until recently, there were no 
guidelines about discontinuation of vancomycin use. In 
September 2008, the first VRE-colonized patient was 
identified in our hospital on the oncology ward. In August 
2009, we identified the first (index) case of VRE infection 
in a pediatric patient in our institution, followed by 4 other 
cases, resulting in three deaths. This led to a series of 
meetings with the Infection Control Service (ICS) team, 
which resulted in the implementation of several practices 
to achieve full adherence to HICPAC guidelines. There-
fore, the objective of this study was to report the results of 
these interventions in vancomycin use and VRE infections 
at our institution.
Material and Methods
Study design
This is a retrospective report on the results of systematic 
interventions in a PICU at Hospital das Clínicas, Faculdade 
de Medicina de Ribeirão Preto, Universidade de São Paulo 
(HC-FMRP-USP), a tertiary-care university hospital, carried 
out between August and September 2009. This unit assists 
patients undergoing major surgical procedures, mostly open 
heart surgery and neurosurgery, and patients from pediatric 
oncology wards with clinical or surgical complications.
Vancomycin use before the interventions
From 1998 to August 2009, our protocol for prophylaxis 
of bacterial infection in children undergoing open heart 
surgery was a) cephazolin (80 mg/kg loading dose plus 
40 mg/kg every 8 h) for patients admitted within 48 h be-
fore surgery, or b) vancomycin (10 mg/kg every 6 h) plus 
amikacin (7.5 mg/kg every 12 h) for those admitted 2 days 
or more before surgery. These regimens were maintained 
for 48 h after surgery. In addition, when sternum closure 
was delayed, antibiotics were continued until 24 h after 
sternum closure. When a postoperative bacterial infection 
was suspected, vancomycin, plus a 3rd- or 4th-generation 
cephalosporin, were started and maintained for at least 7 
days even when cultures resulted negative or identified 
a microorganism other than MRSA. Blood cultures were 
collected as single samples.
Interventions
After the identification of the first VRE infection, we 
started a series of meetings with the ICS staff to plan 
interventions at the following three levels: patient care, 
microbiological surveillance, and medical and nursing staff 
training. 1) Patient care: full compliance with the HICPAC 
guidelines for adequate use of vancomycin, bathing with 
a 2% chlorhexidine solution the night before surgery and 
on the day of surgery, changes in surgical prophylaxis (use 
of cephazolin for children admitted up to 5 days before 
surgery and those with negative routine screening cultures, 
MRSA decolonization with chlorhexidine bathing plus a 
nasal argentum sulfadiazine solution for 5 days for patients 
colonized with MRSA, adjustments of dose and timing of 
prophylactic antibiotics, maintenance of prophylaxis only 
for 24 h even in patients with an open chest, new loading 
doses right before chest closure), changes in treatment of 
postoperative infections (starting vancomycin only if deep 
surgical site- or central venous catheter-related infection or 
isolated MRSA or severe infections with sepsis was present 
and discontinuation if no MRSA was identified within the 
first 72 h), collection of paired samples for blood cultures, 
geographic cohorting of patients with documented MRSA 
or VRE, and contact precautions and dedicated patient 
equipment. 2) Staff training: lectures on HICPAC guidelines, 
antibiotics stewardship, antisepsis for blood culture sample 
collection, emphasizing the importance of the antibiotic 
loading dose given immediately before the beginning of 
surgery, attention to extra doses of intraoperative antibiotics, 
careful hand degermation with 2% chlorhexidine at unit entry 
plus hand cleaning with gel alcohol, aseptic techniques for 
invasive procedures, routine environmental cleaning and 
disinfection, and avoiding hypothermia and hyperglycemia. 
3) Microbiological surveillance: routine collection of surveil-
lance cultures from patients transferred from other hospitals 
(blood, urine, tracheal, or nasal specimens, rectal swabs), 
routine collection of blood cultures and tracheal aspirates 
or nasal swabs from patients colonized with MRSA, and 
routine collection of blood cultures and rectal swabs from 
patients colonized with VRE.
Data collection
Data were collected from the ICS computer-based da-
tabase and from the electronic prescription system, includ-
ing: number of admissions, mean length-of-stay, mortality, 
prescriptions of vancomycin, dose of vancomycin used, 
and number and agents of infections, including VRE. The 
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National Nosocomial Infections Surveillance (NNIS) system 
was used for nosocomial infection surveillance and report 
(17). VRE nosocomial infections were diagnosed according 
to CDC/NHSN criteria (18).
Statistical analysis
Data are reported as raw numbers and proportions, or 
as means ± SD. There was no hypothesis test.
Results
In 2008, after the identification of the first VRE-colonized 
patient (rectal swab), VRE was isolated from 14 other pa-
tients (one from the surgical site and 13 from 
rectal swabs), and 12 were considered infected. 
All these patients were adults, and VRE was 
never found in pediatric patients until August 
2009. In 2009, VRE was isolated from 29 adult 
plus 5 pediatric patients at many hospital sites, 
and 24 were considered infected. Only vanco-
mycin-resistant Enterococcus faecium (VREfm) 
was isolated from all patients using automated 
methods with manual confirmation.
Since 1998, our unit has admitted 3065 
patients (mean of 236 patients per year) or 
2230 patients-day per year (mean of the last 4 
years), with an incidence density of nosocomial 
infection of 23 episodes/patient-day and overall 
mortality rate of 11.8% (both in 2009). The use 
of vancomycin was about 200 mg/patients-
day during 2007, and in March 2008 we noted 
a progressive increase in vancomycin use, 
peaking in July 2008 and August 2009 (Figure 
1). At that time, the first case of VRE infection 
was identified, followed by 4 other cases (Table 
1), which resulted in 3 deaths (1 infected and 
2 colonized). In all cases, only VREfm was 
isolated. VRE was not isolated from any other 
pediatric unit within our hospital.
Upon identification of the first case, the inter-
ventions were made. We then noted a significant 
75% reduction in vancomycin prescription and 
use and 4 months later the last case of VREfm 
infection was identified. The survivors remained 
colonized until hospital discharge.
After the interventions, we noticed a transient 
increase in PICU length-of-stay and mortality 
(Figure 1). Since then, the use of vancomycin 
has remained relatively constant and strict, 
and despite the identification of 44 new cases 
of VRE-infected or colonized patients in our 
hospital, no other cases of VRE infection or 
colonization have been identified in our unit, 
and length-of-stay and mortality have returned 
to baseline.
Discussion
We have shown a significant reduction of vancomycin 
prescription and use and the control of vancomycin-resistant 
enterococcus spread in a Brazilian tertiary PICU after 
implementation of strict policies for vancomycin use and 
full compliance with HICPAC guidelines.
Decreasing the risk of infections with multidrug-resistant 
organisms by reducing overuse and misuse of antimicro-
bials is a major challenge to clinicians (1). Vancomycin 
misuse creates a selective pressure for the emergence 
of resistant bacteria, as we experienced. The proportion 
on VREfm increased over 10 years around the world, 
Figure 1. A, Vancomycin use per patient-day (mg x 100), number of van-
comycin-resistant enterococci (VRE) cases per 100 patients-day; B, mean 
length-of-stay (with linear trend), and C, mortality (with polynomial trend) from 
January 2009 to August 2010.
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whereas vancomycin-resistant E. faecalis (VREfc) remained 
constant. In Brazil, VREfc predominated until 1999, when 
dissemination of VREfm increased (19). Only VREfm was 
present in our patients.
Efforts should be directed at medical education on 
HICPAC guidelines and institutional policies for strict van-
comycin use in order to control the emergence of resistant 
bacteria, as well as to reduce patient morbidity and mortal-
ity and healthcare costs (1,9). In the presence of a VRE 
outbreak, recommendations include testing enterococcal 
isolates for vancomycin resistance, fecal screening to de-
tect patients colonized with VRE and intensifying control 
programs and staff education (20). Reports on measures 
for the control of vancomycin use in a tertiary-care hospital, 
including lectures to medical staff, dissemination of HICPAC 
guidelines and computer-based automatic stop vancomycin 
order after 72 h and electronic alerts, have shown a 22% 
reduction in vancomycin prescriptions, but most prescrip-
tions were still inappropriate according to HICPAC guidelines 
(21). After the interventions, we showed a 75% reduction 
in vancomycin use in our unit.
Several other reports have been published on successful 
efforts to control outbreaks of VRE in many settings, includ-
ing general wards, hematology units, and general, neuro-
surgical and neonatal intensive care units (16,19,22-27). 
These interventions included creation of VRE control teams, 
cohorting of VRE carriers, active surveillance cultures for 
VRE, environmental cultures and cleaning, reinforcement of 
hand hygiene, and antibiotic control policies and education 
for the entire hospital staff (15,19,22,24,25,27). One report 
of lack of effectiveness of such interventions in VRE control 
has associated it to the emergence of the ST203 E. faecium 
clone with the acquired vanB locus (26).
The present report has some limitations. First, we did not 
evaluate the effects of interventions on morbidity or costs 
of hospitalization. Second, in addition to close monitoring 
of vancomycin use, rates of compliance with VRE isola-
tion precautions and hand washing were not actively and 
systematically assessed.
In conclusion, we showed that a bundle intervention 
aiming at the strict control of vancomycin use and full 
compliance with the HICPAC guidelines, along with contact 
precautions and hand-hygiene promotion can be effective in 
reducing vancomycin use and the emergence and spread 
of vancomycin-resistant bacteria in a tertiary-care PICU.
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Table 1. Main characteristics of patients infected or colonized with vancomycin-resistant enterococci.
Patient Gender Age 
(months)
Diagnosis Vancomycin 
use
Date of VREfm 
identification
Site of 
identification
Outcome Hospital 
length-of-stay 
1 Female 8.9 Down syndrome, tetralogy 
of Fallot (operated)
49 days 08-10-2009 Mediastinum 
(infection)
Discharge 127 days
2 Female 6.5 Down syndrome, atrial 
septal defect plus patent 
ductus arteriosus (both 
operated)
20 days 08-14-2009 Blood stream 
(infection)
Discharge  41 days
3 Male 3.1 Situs inversus totalis, 
biliary atresia, congenital 
complete atrioventricular 
block, complex heart 
malformations (palliated)
19 days 08-28-2009 Rectal swab 
(colonization)
Death 154 days
4 Male 5 Bell’s paralysis, total 
atrioventricular septal 
defect (operated), 
vesicoureteral reflux
 1 day 10-19-2009 Rectal swab 
(colonization)
Death  41 days
5 Female 2 Ventricular septal defect, 
atrial septal defect, patent 
ductus arteriosus, deep 
vein thrombosis, renal 
failure requiring peritoneal 
dialysis
 3 days 12-07-2009 Peritoneal 
fluid (infection)
Death  27 days
VREfm = vancomycin-resistant Enterococcus faecium.
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